Surrozen, Inc. (NASDAQ:SRZN) Short Interest Down 59.7% in December

Surrozen, Inc. (NASDAQ:SRZNGet Free Report) was the target of a significant decline in short interest in December. As of December 31st, there was short interest totalling 4,800 shares, a decline of 59.7% from the December 15th total of 11,900 shares. Based on an average daily volume of 10,100 shares, the short-interest ratio is presently 0.5 days. Approximately 0.2% of the shares of the company are sold short.

Surrozen Stock Performance

SRZN stock traded down $0.44 during trading on Friday, hitting $9.11. The company had a trading volume of 4,641 shares, compared to its average volume of 18,360. Surrozen has a 1-year low of $4.50 and a 1-year high of $20.70. The firm has a 50-day moving average price of $7.76 and a 200-day moving average price of $8.38.

Surrozen (NASDAQ:SRZNGet Free Report) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($4.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.20) by ($0.15). As a group, equities research analysts forecast that Surrozen will post -20.54 EPS for the current year.

Institutional Investors Weigh In On Surrozen

A number of institutional investors have recently added to or reduced their stakes in SRZN. Renaissance Technologies LLC boosted its holdings in Surrozen by 284.6% in the 1st quarter. Renaissance Technologies LLC now owns 102,298 shares of the company’s stock valued at $62,000 after purchasing an additional 75,700 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Surrozen during the 4th quarter worth approximately $72,000. Morgan Stanley boosted its stake in shares of Surrozen by 10,427.8% during the 4th quarter. Morgan Stanley now owns 528,179 shares of the company’s stock worth $307,000 after acquiring an additional 523,162 shares in the last quarter. Bank of Montreal Can purchased a new stake in shares of Surrozen during the 1st quarter worth approximately $377,000. Finally, Trustees of Columbia University in the City of New York purchased a new stake in shares of Surrozen during the 4th quarter worth approximately $419,000. Hedge funds and other institutional investors own 51.27% of the company’s stock.

About Surrozen

(Get Free Report)

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

See Also

Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with's FREE daily email newsletter.